

- **Name:** Jaekyung Cheon
 - **Current Position & Affiliation:** Assistant professor, CHA Bundang Medical Center
 - **Country:** Republic of Korea
-

- **Educational Background:**

- MD, College of Medicine, Hallym University, Chuncheon, Korea, 2004-2010
- MS, Internal Medicine, Graduate School, Ulsan University, Seoul, Korea, 2015-2018

- **Professional Experience:**

- Intern & Residency in Internal Medicine, Asan Medical Center, Seoul, Korea, 2010-2015
- Clinical Fellow, Department of Medical Oncology, Asan Medical Center, Seoul, Korea, 2016-2017
- Clinical Assistant Professor, Department of Hematology-Oncology, Ulsan, Korea, 2017-2021
- Assistant Professor, Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea, 2021-present
-

- **Professional Organizations:**

- Korean Society of Medical Oncology
- Korean Cancer Study Group
- Korean Cancer Association
- American Society of Clinical Oncology
- European Society of Medical Oncology

- **Main Scientific Publications:**

1. Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis. *Liver Cancer*, 2020;9:613–624. **(co-first author)**
2. Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. *Support Care Cancer*, 2021;29(2):975-986. **(first author)**
3. Active tuberculosis risk associated with malignancies: an 18-year retrospective cohort study in Korea. *J Thorac Dis*, 2020;12(9):4950-4959. **(first author)**
4. “Teachable Moment”: Effects of an Educational Program on Knowledge and Quality of Life of Korean Breast Cancer Survivors. *J Cancer Educ*, 2020. **(first author)**
5. Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. *BMC Palliative Care*, 2021;27;20(1):63. **(co-corresponding author)**
6. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. *Ther Adv Med Oncol*, 2021;19;13:17588359211003053. **(co-first author)**

author)

7. Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea. *Support Care Cancer*, 2021;29(9):5383-5390. **(co-first author)**
8. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. *Ther Adv Med Oncol*, 2021 Aug 7;13:17588359211035983. **(co-first author)**
9. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. *Liver Int*, 2022;42(3):674-681. **(co-first author)**
10. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. *Cancers*, 2022;14(7):1747. **(co-first author)**
11. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. *Gastric Cancer*, 2022. doi: 10.1007/s10120-022-01298-6. Online ahead of print. **(co-first author)**
12. The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. *Ther Adv Med Oncol*, 2022;14:1-13. **(co-corresponding author)**